“One area in which China is making big gains is in the regulatory environment, which will help China consolidate on this in 2019 and beyond…National Medical Products Administration (NMPA) reforms have been happening at a rapid pace, with escalating numbers of drug applications with priority review in the face of increased public engagement on medicines access. The latter was triggered in part by a hugely successful movie called Dying to Survive—a comedy about illegally importing leukemia drugs—which raised $200 million in its opening weekend and brought the issue of access to a wide audience. Faster review of applications for clinical trials is also helping: With the latest amendment to the NMPA’s review process, applications are approved if the agency does not respond within 60 working days of filing.” writes Taylor.
Taylor goes on to discuss a challenge, the migration of talent, particularly multinational pharma companies bleeding top China-based executives to the country’s emerging biotech leaders. He also states that there are some areas where China is threatening to overtake the west in biotech R&D and lose its reputation as a “fast-follower.”
China’s R&D is poised to do well in the future, and the R&D industry and the rest of the world is watching in anticipation for what is to come from them in 2019.
We encourage you to read the full article by Phil Taylor, click this link to read the original article: https://www.fiercebiotech.com/biotech/can-china-s-r-d-sector-shake-its-reputational-issues-2019
